Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

<p>Information of ATCC cell lines</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Seung Yeon Oh (15051017) (author)
Бусад зохиолчид:	You Won Lee (15051020) (author), Eun Ji Lee (15051023) (author), Jae Hwan Kim (15051026) (author), YoungJoon Park (15051029) (author), Seong Gu Heo (15032490) (author), Mi Ra Yu (15051032) (author), Min Hee Hong (15014541) (author), John DaSilva (15051035) (author), Christopher Daly (15030374) (author), Byoung Chul Cho (15032496) (author), Sun Min Lim (15051038) (author), Mi Ran Yun (15032484) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Therapeutic Research and Development Drug Resistance Clinical drug resistance Lung Cancer Translational Research
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Table S5 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
-н: Nina Müller (16721126)
Хэвлэсэн: (2025)

Table S6 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
-н: Nina Müller (16721126)
Хэвлэсэн: (2025)

Table S7 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
-н: Nina Müller (16721126)
Хэвлэсэн: (2025)

Table S8 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
-н: Nina Müller (16721126)
Хэвлэсэн: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
-н: Nicole A. Traphagen (16677391)
Хэвлэсэн: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
-н: Nicole A. Traphagen (16677391)
Хэвлэсэн: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
-н: Phyllis S.Y. Chong (17141520)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_4vr47li1ugr8k9v6ajq7d70ero